

**Westminster Business Forum Keynote Seminar:  
UK health life sciences - innovation, investment and global competitiveness**

Timing: Morning, Tuesday, 17<sup>th</sup> June 2014

Venue: Sixty One Whitehall, London SW1A 2ET

Agenda subject to change



- 8.30 - 9.00 Registration and coffee
- 9.00 - 9.05 **Chairman's opening remarks**  
**Ifan Evans**, Deputy Director, Healthcare Innovation, Welsh Government
- 9.05 - 9.25 **UK life sciences in an international market**  
*How competitive is the UK in the global market for life sciences, and what can be learnt from its competitors across Europe and internationally?*  
**Professor Hilary Thomas**, Head of Life Sciences & Healthcare Strategy Practice, KPMG  
Questions and comments from the floor
- 9.25 - 9.55 **Priorities from the human healthcare industry - latest thinking on the delivery of Government strategy**  
**Stephen Whitehead**, Chief Executive, Association of the British Pharmaceutical Industry (ABPI)  
**Andy Taylor**, Executive Director, Government Policy, Association of British Healthcare Industries (ABHI)  
Questions and comments from the floor
- 9.55 - 10.40 **Next steps for the Strategy for UK Life Sciences - infrastructure, partnerships & supporting healthcare innovation**  
*What impact has the Strategy for UK Life Sciences had so far on competitiveness and growth, and what further action is required in areas such as developing research infrastructure and partnerships, and overcoming barriers to healthcare innovation? In what ways has the life sciences ecosystem developed since the last strategy update, and how can universities, industry and the NHS work together more effectively in the future? Has Government strategy delivered on its ambitions to make it easier for researchers to commercialise academic research, and what can be learnt from initiatives such as the Biomedical Catalyst and the Cell Therapy Catapult? What more can be done to enhance the landscape for developing, licensing and procuring innovative medicines, and what are the key challenges for delivering a workable Early Access to Medicines Scheme? To what extent have recommendations in the Innovation Health and Wealth (IHW) report been delivered - particularly in relation to accelerating payment coverage for innovative technologies, and ensuring that commissioning decisions support the adoption of proven innovations? What impact have wider measures - including the Patent Box and the use of R&D tax credits - had on incentivising investment in UK life sciences?*  
**Professor Richard King**, Clinical Lead for Innovation, University Hospitals Coventry and Warwickshire NHS Trust  
**Professor David Ford**, Professor of Health Informatics, Swansea University and Lead, The Life Science Exchange  
**Professor David Fish**, Managing Director, UCLPartners  
**Dr Jonathan Peat**, Business Development Manager, QuantuMDx  
Questions and comments from the floor
- 10.40 - 10.45 **Chairman's closing remarks**  
**Ifan Evans**, Deputy Director, Healthcare Innovation, Welsh Government
- 10.45 - 11.10 Coffee
- 11.10 - 11.15 **Chairman's opening remarks**  
**Ann McKechin MP**, Member, Business, Innovation and Skills Select Committee
- 11.15 - 11.55 **Growth, competitiveness and regulation**  
*Latest thinking on how key stakeholders and policymakers can develop future opportunities for growth and competitiveness in UK life sciences.*
- Product development and market access**  
**Dr Leeza Osipenko**, Associate Director, Scientific Advice, NICE
- Streamlining the regulation of research**  
**Dr Allison Jeynes-Ellis**, Non-Executive Director, Health Research Authority
- Developing world-class medical research**  
**Dr Jim Smith**, Deputy Chief Executive Officer and Chief of Strategy, Medical Research Council, and Director, National Institute for Medical Research
- Genomic technology adoption - a case study on generating economic value**  
**Professor Tim Hubbard**, Head of Bioinformatics, Genomics England
- Skills and apprenticeships - prospects for attracting and developing talent**  
**Dr Stephen Rosevear**, Strategy Director, Cogent Sector Skills Council
- 11.55 - 12.25 Questions and comments from the floor
- 12.25 - 12.55 **Creating a business environment for investment and growth - emerging opportunities and challenges**  
**Dr Mark Treherne**, Chief Executive, Life Science Investment Organisation, UK Trade & Investment  
**Mark Samuels**, Managing Director, NIHR Office for Clinical Research Infrastructure (NOCRI)  
Questions and comments from the floor
- 12.55 - 13.00 **Chairman's and Westminster Business Forum closing remarks**  
**Ann McKechin MP**, Member, Business, Innovation and Skills Select Committee  
**Marc Gammon**, Senior Producer, Westminster Business Forum